Epstein-Barr virus–positive nodular lymphocyte predominant Hodgkin lymphoma

Wang, Shi; Medeiros, L. Jeffrey; Xu-Monette, Zijun Y.; Zhang, Shanxiang; O’Malley, Dennis P.; Orazi, Attilio; Zuo, Zhuang; Bueso‐Ramos, Carlos E.; Yin, C. Cameron; Liu, Zhiyu; Miranda, Roberto N.; Young, Ken H.

doi:10.1016/j.anndiagpath.2014.03.007

Cited by 23 publications

(24 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While L&H cells retain the expression of typical B-cell antigens such as CD20 and CD19, HRS cells of classical HL have an unusual phenotype in which the B-cell gene expression programme is largely extinguished. Although recent studies suggest that a small proportion of NLPHL cases harbour the Epstein-Barr virus (EBV) (Wang et al 2014;Huppmann et al 2014), here we focus on classical HL in which the link with EBV is well established.…”

Section: Introductionmentioning

confidence: 99%

Contribution of the Epstein-Barr Virus to the Pathogenesis of Hodgkin Lymphoma

Murray

Bell

2015

Current Topics in Microbiology and Immunology

View full text Add to dashboard Cite

The morphology of the pathognomonic Hodgkin and Reed-Sternberg cells (HRS) of Hodgkin lymphoma was described over a century ago, yet it was only relatively recently that the B-cell origin of these cells was identified. In a proportion of cases, HRS cells harbour monoclonal forms of the B lymphotropic Epstein-Barr virus (EBV). This review summarises current knowledge of the pathogenesis of Hodgkin lymphoma with a particular emphasis on the contribution of EBV.

show abstract

Section: Introductionmentioning

confidence: 99%

Contribution of the Epstein-Barr Virus to the Pathogenesis of Hodgkin Lymphoma

Murray

Bell

2015

Current Topics in Microbiology and Immunology

View full text Add to dashboard Cite

show abstract

“…There are two distinct forms of HL, known as classical Hodgkin lymphoma (cHL) and nodular lymphocyte- predominant Hodgkin lymphoma (NLPHL), that are separated on the basis of morphologic, immunophenotypic, and clinical differences. Despite earlier reports to the contrary, recent studies suggest that a small proportion of NLPHL cases harbor Epstein-Barr virus (EBV) [1] , [2] . However, this review focuses on cHL where the link with EBV is most clearly established.…”

mentioning

confidence: 87%

Epstein-Barr virus and the origin of Hodgkin lymphoma

Vockerodt

Cader²,

Shannon-Lowe

et al. 2014

Chin J Cancer

View full text Add to dashboard Cite

Although Epstein-Barr virus (EBV) is present in the malignant Hodgkin/Reed-Sternberg (HRS) cells of a proportion of cases of classical Hodgkin lymphoma (cHL), how the virus contributes to the pathogenesis of this disease remains poorly defined. It is clear from the studies of other EBV-associated cancers that the virus is usually not sufficient for tumor development and that other oncogenic co-factors are required. This article reviews what is known about the contribution of EBV to the pathogenesis of cHL and focuses on emerging evidence implicating chronic inflammation as a potential oncogenic co-factor in this malignancy.

show abstract

“…Most pathologist use EBVexpression in the neoplastic cells as an argument against a diagnosis nodular lymphocytepredominant HL (NLPHL). According to Wang et al [9], this is probably not completely correct. They reported on eight cases of EBV-positive NLPHL occurring in patients in the USA.…”

Section: Hodgkin Lymphomamentioning

confidence: 98%

New developments in the pathology of malignant lymphoma. A review of the literature published from June–August 2014

Krieken

2014

J Hematopathol

View full text Add to dashboard Cite

Epstein-Barr virus–positive nodular lymphocyte predominant Hodgkin lymphoma

Cited by 23 publications

References 27 publications

Contribution of the Epstein-Barr Virus to the Pathogenesis of Hodgkin Lymphoma

Contribution of the Epstein-Barr Virus to the Pathogenesis of Hodgkin Lymphoma

Epstein-Barr virus and the origin of Hodgkin lymphoma

New developments in the pathology of malignant lymphoma. A review of the literature published from June–August 2014

Contact Info

Product

Resources

About